evan – Page 2 – Lophos Pharmaceuticals

Lophos Pharmaceuticals Partners With Carmichael Engineering Ltd. for HVAC Project, Anticipates Expedited Building Occupancy

by evan in Uncategorized March 5, 2024

NAPANEE, Ontario, March 05, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos” or the “Company”) (CSE:MESC) is pleased to announce its subsidiary, Lophos Pharmaceuticals Corp., has selected Carmichael Engineering Ltd., a renowned HVAC engineering and construction firm headquartered in Belleville, ON, to drive the completion of its HVAC project and expedite occupancy at the site. […]

Lophos Confirms Appearance at Benzinga Capital Conference in Hollywood, Florida and Finalizes Annual General Meeting

by evan in Uncategorized February 28, 2024

NAPANEE, Ontario, Feb. 28, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is thrilled to announce its wholly-owned subsidiary, Lophos Pharmaceuticals Corp., will participate in the upcoming Benzinga Capital Conference, scheduled to take place in Hollywood, Florida, on April 16-17, 2024. Lophos will be showcasing their latest achievements and initiatives during […]

Lophos Pharmaceuticals Corp. Finalizes the Development of a New Research Protocol for Lophophora Williamsii (Peyote)

by evan in Uncategorized February 14, 2024

NAPANEE, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is thrilled to provide further insights into the accomplishments of its wholly-owned subsidiary, Lophos Pharmaceuticals Corp., and proudly announces the finalization of a pioneering research protocol, aimed at identifying the optimal soil conditions for fostering the growth of Lophophora […]

Lophos Pharmaceuticals Corp. Finalizes the Development of a New Synthetic Mescaline Protocol

by evan in Uncategorized February 8, 2024

NAPANEE, Ontario, Feb. 08, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is thrilled to provide further insights into the accomplishments of its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. Lophos Pharmaceuticals Corp. proudly announces the finalization of its pioneering procedure for the production of synthetic mescaline. This innovative protocol defines the process, facilitating […]

Lophos Pharmaceuticals Corp. Finalizes Product Release Specifications for Fresh and Dried Peyote (Lophophora williamsii)

by evan in Uncategorized January 31, 2024

NAPANEE, Ontario, Jan. 31, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is thrilled to provide further insights into the accomplishments of its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. The subsidiary has achieved a noteworthy milestone in the cultivation and ethical distribution of psychoactive plants and is delighted to announce the formalization […]

Health Canada Endorses Lophophora Williamsii, Elevating Lophos Holdings Inc. as a Leader in Natural Health Innovation

by evan in Press Releases January 23, 2024

Napanee, Ontario, January 23, 2024 – Lophos Holdings Inc. (“Lophos”) (CSE:MESC), a trailblazerin the production of Lophophora williamsii (peyote), proudly announces a significant stride inthe natural health sector. Health Canada’s recent recognition of Lophophora williamsii as aNatural Health Product ingredient marks a pivotal moment in the therapeutic use ofpsychoactive plants, reinforcing Lophos’ position at the […]

Lophos Pharmaceuticals Corp. Receives Health Canada Approval for Expanded Controlled Substance Operations Following HVAC Revisions

by evan in Uncategorized November 21, 2023

NAPANEE, Ontario, Nov. 21, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos“, or the “Company“) (CSE:MESC) is delighted to share additional information on its wholly-owned subsidiary, Lophos Pharmaceuticals Corp., which has achieved an important milestone by obtaining a significant amendment to its Controlled Substance Dealer’s license by Health Canada for its facility located in Napanee, […]

Lophos Secures Game-Changing Controlled Substance Dealer’s License with the Expertise of Canalytica Corp.

by evan in Press Releases October 10, 2023

NAPANEE, Ontario, Oct. 10, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos“, or the “Company“) (CSE:MESC) is delighted to share additional information on its wholly-owned subsidiary, Lophos Pharmaceuticals Corp., which has achieved a significant milestone by obtaining a Controlled Substance Dealer’s License from Health Canada for their facility located in Napanee, Ontario. Facility Overview Permitted […]

Lophos Opens Early Enrollment for Peyote Sales and Appoints Market Maker

by evan in Press Releases September 19, 2023

VANCOUVER, British Columbia, Sept. 19, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos“, or the “Company“) (CSE:MESC) is delighted to share a substantial milestone. Its wholly owned subsidiary, Lophos Pharmaceuticals Corp., has initiated the early enrollment phase for acquiring peyote cactus (Lophophora williamsi) via its official website, http://www.lophos.com. Interested parties can now register with Lophos […]

Lophos Announces Listing on the Canadian Securities Exchange

by evan in Press Releases August 31, 2023

Vancouver, British Columbia, August 31, 2023 – Lophos Holdings Inc. (“Lophos“, or the “Company“) is pleased to announce that its common shares have been approved for listing on the Canadian Securities Exchange (the “CSE“) and the Company expects to commence trading on the CSE on or around September 06, 2023, under the ticker symbol “MESC“. […]

All posts by: evan